Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
  • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
  • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J75/00—Processes for the preparation of steroids in general
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention belongs to the field of pharmaceutical synthesis, and specifically relates to a cholic acid derivative, and the preparation method and use thereof.
• the farnesyl derivative X receptor is a member of the hormone nuclear receptor superfamily, which is mainly expressed in liver, small intestine, kidney and adrenal gland, and is less expressed in adipose tissue and heart. It is named as FXR because farnesol is thought as its ligand initially.
• FXR ligand directly binds to the ligand-binding region(LBD) of carboxy terminal of FXR, the conformation of the nuclear receptor changes and forms a heterodimer with the retinal derivative receptor (RXR), which is ultimately integrated with the specific FXR DNA response element of target gene to regulate the transcription of the target gene, involved in the regulation of sugar and lipid metabolism.
• RXR retinal derivative receptor
• Primary bile acid chenodeoxycholic acid is the most effective ligand for FXR, and secondary bile acid lithocholic acid and deoxycholic acid can also activate FXR.
• FXR ligands such as 6-ECDCA, GW4064, etc.
• the main target genes of FXR include bile salt export pump (BSEP), bile acid binding protein (IBABP) and small heterodimeric partner receptor (SHP), etc.
• FXR regulates the expression of these genes by reacting with FXR reaction elements (FXRE) on these gene promoters.
• FXR agonists either can increase bile acid-dependent bile flow by stimulating bile salt export pump (BSEP), or can reduce cholestasis by stimulating MRP2 to increase non-bile acid-dependent bile flow.
• BSEP stimulating bile salt export pump
• MRP2 cholestasis by stimulating MRP2 to increase non-bile acid-dependent bile flow.
• FXR is expected to be a target for screening new drug which can treat other metabolic diseases, including cholestatic diseases and nonalcoholic steatohepatitis and the like.
• FXR agonists may be valuable in the treatment and research of diseases including atherosclerosis, cholestatic diseases caused by bile acid disorder, liver fibrosis, cirrhosis, cancer and the like (please refer to table 1).
• Table 1 Table 1.
• the diseases can be benefited from FXR agonists • arteriosclerosis • bile acid disorders benign intrahepatic cholestasis progressive familial intrahepatic cholestasis (type 1, 2 and 3) primary biliary cirrhosis primary biliary cirrhosis, primary sclerosing cholangitis • cancer • cholesterol gallstone • diabetes • dyslipidemia • fibrosis diseases chronic hepatitis (type B and C type) non-viral hepatitis • inflammatory bowel disease • alteration of intestinal flora • liver transplantation • non-alcoholic fattv liver disease and non-alcoholic steatohepatitis
• cholic acid derivatives as represented by formula (I). These compounds have a significant agonistic effect on FXR activity, and can be used in the treatment of FXR mediated diseases comprising cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesterolemia, hyperlipidemia and chronic hepatitis diseases, chronic liver diseases, gastrointestinal diseases, nephrosis, heart vascular diseases, metabolic diseases, cancer (for example colorectal cancer) or neurological signs, such as strokes and other diseases, with a wide range of medical applications, and are expected to be developed into a new generation of FXR agonist.
• diseases comprising cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesterolemia, hyperlipidemia and chronic hepatitis diseases, chronic liver diseases, gastrointestinal diseases, nephrosis, heart vascular diseases, metabolic diseases, cancer (for example colorectal cancer) or neurological signs, such as strokes and other diseases, with a wide range of medical applications, and are expected to be developed into a new generation of FXR
• the present invention provides a cholic acid derivatives of formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof: wherein,
• the C 1-8 alkyl is preferred selected from C 1-6 alkyl, and more preferred selected from C 1-3 alkyl; the C 1-8 alkoxy is preferred selected from C 1-6 alkoxy, and more preferred selected from C 1-3 alkoxy; the C 3-8 cycloalkyl preferred selected from C 3-6 cycloalkyl; the C 3-8 cycloalkoxy is preferred selected from C 3-6 cycloalkoxy; the C 2-8 alkenyl is preferred selected from C 2-4 alkenyl; the C 2-8 alkynyl is preferred selected from C 2-4 alkynyl.
• R 1 is selected from the group consisting of hydrogen, fluorine, methyl, trifluoromethyl, ethyl and isopropyl;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• R 2 is selected from the group consisting of hydrogen, methyl, ethyl and isopropyl; R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• R 3 is selected from the group consisting of hydrogen, methyl, ethyl and isopropyl; R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• R 3 is selected from the group consisting of hydrogen and methyl; R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (II):
• R 1 is hydrogen;
• R 3 is selected from the group consisting of hydrogen and methyl;
• R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (III):
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (IV): wherein, R 4 is selected from the group consisting of: R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 , Z and n are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention when R 4 is selected from the group consisting of n is 1; when R 4 is n is 0; R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 and Z are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is selected from the group consisting of: or selected from the group consisting of: or selected from the compound of:
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (V): wherein, X 1 , X 2 , R 2 , R 8 , R 9 and R 10 are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is selected from the group consisting of:
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (VI): wherein, Y 1 , Y 2 , R 2 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is selected from the group consisting of:
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is a compound of formula (VII): or a compound as defined below: including two isomerides as defined below: wherein, R 2 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 and Z are as defined in the compound of formula (I).
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is selected from the group consisting of:
• the present invention provides the cholic acid derivatives of formula (VIII), the stereoisomer or the pharmaceutically acceptable salt thereof, the compound of formula (VIII) is as defined below:
• the cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof according to the present invention is selected from the group consisting of:
• the present invention provides a process for preparing the aforesaid cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof, comprising the steps of: or or or or or or or or wherein, R 2 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , X 1 , X 2 , Y 1 , Y 2 and Z are as defined in the compound of formula (I).
• Pg 1 is hydroxyl protective group, and is preferred selected from the group consisting of C 1-4 alkyl and benzyl
• Pg 2 is hydroxyl protective group, and is preferred selected from the group consisting of C 1-4 alkyl and acetyl.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of the aforesaid cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof and a pharmaceutical acceptable carrier.
• the present invention provides a use of the aforesaid cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof, or the aforesaid pharmaceutical composition in the preparation of a medicament for prevention or treating FXR mediated diseases and conditions.
• FXR mediated diseases and conditions are selected from the group consisting of cardiovascular disease, hypercholesterolemia, hyperlipidemia and chronic hepatitis disease, chronic liver disease, gastrointestinal disease, nephrosis, cerebrovascular disease, metabolic disease and cancer.
• the chronic liver disease is selected from the group consisting of primary cirrhosis (PBC), cerebrotendinous Xanthomatosis (CTX), primary sclerosing cholecystitis (PSC), cholestasis caused by drug, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), cholestasis of bacterial overgrowth or pyemia, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), graft versus host disease related to liver transplantation, regeneration of living donor liver transplantation, congenital hepatic fibrosis, choledocholithiasis, granulation liver disease, intrahepatic and extrahepatic malignant tumor, Sjogren syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatos
• PBC primary
• the gastrointestinal disease is selected from the group consisting of inflammatory bowel disease (IBD) (incluing Crohn's disease and ulcerative enteritis), irritable bowel syndrome (IBS), bacterial overgrowth, nutrient malabsorption, colonitis after reflection and microscopic colitis.
• IBD inflammatory bowel disease
• IBS irritable bowel syndrome
• the nephrosis is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephropathy, chronic glomerulitis, chronic transplant glomerulopathy, chronic interstitial nephritis and polycystic kidney disease.
• FSGS focal segmental glomerulosclerosis
• hypertensive nephropathy chronic glomerulitis
• chronic transplant glomerulopathy chronic interstitial nephritis and polycystic kidney disease.
• the cardiovascular disease is selected from the group consisting of arteriosclerosis, arteriosclerosis, atherosclerosis, dyslipidemia, hypercholesterolemia and hypertriglyceridemia.
• the metabolic disease is selected from the group consisting of insulin resistance, type I diabetes, type II diabetes and obesity.
• the cerebrovascular disease is stroke.
• the cancer is selected from the group consisting of colorectal cancer and liver cancer.
• the present invention provides a method for preventing and treating FXR mediated diseases and conditions, comprising administationg of a therapeutically effective amount of the aforesaid cholic acid derivatives, the stereoisomer or the pharmaceutically acceptable salt thereof, or the aforesaid pharmaceutical composition.
• C 1-8 alkyl refers to a straight chain or branched chain alkyl group having 1 to 8 carbon atoms.
• Alkyl refers to a saturated aliphatic hydrocarbon group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl,
• Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent.
• C 3-8 cycloalkyl refers to a cycloalkyl group having 3 to 8 carbon atoms, for example:
• fused cycloalkyl refers to an all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with another ring, wherein one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated ⁇ electronic system. According to the number of membered rings, the fused-cycloalkyl can be divided into bicyclic, tricyclic, tetracyclic and polycyclic fused cycloalkyl. The non-limiting examples of the fused cycloalkyl include:
• Bridged cycloalkyl refers to an all-carbon polycyclic group in which any two rings in the system share two disconnected carbon atoms, wherein these rings can contain one or more double bonds, but none of the rings has a completely conjugated ⁇ electronic system. According to the number of membered rings, the bridged cycloalkyl can be divided into bicyclic, tricyclic, tetracyclic and polycyclic bridged cycloalkyl. The non-limiting examples of the bridged cycloalkyl include:
• the cycloalkyl can be fused to the ring of aryl, heteroaryl or heterocyclyl, wherein the ring connected with the parent structure is the cycloalkyl, and the non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptylalkyl and the like.
• Alkoxy refers to an -O-(alkyl), wherein the alkyl is as defined above.
• C 1-8 alkoxy refers to an alkoxy having 1 to 8 carbons, and the non-limiting examples include methoxy, ethoxy, propoxy, butoxy and the like.
• Cycloalkoxy refers to an -O-(unsubstituted cycloalkyl), wherein the cycloalkyl is as defined above.
• C 3-8 cycloalkoxy refers to a cycloalkoxy group having 3 to 8 carbons, and the non-limiting examples include cyclopropoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like.
• HaloC 1-8 alkyl refers to a C 1-8 alkyl group wherein hydrogens in the alkyl are substituted by fluorine, chlorine, bromine and iodine atoms, for example, difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl and the like.
• C(O)R 12 refers to a carbonyl group substituted with R 12 .
• P(O)R 12 R 13 refers to a phosphoryl substituted with R 12 and R 13 , wherein R 12 and R 13 are optionally identical or different.
• PE refers to petroleum ether
• EA refers to ethyl acetate
• THF tetrahydrofuran
• DCM dichloromethane
• CDI N,N-carbonyldiimidazole
• DMF N,N-dimethylformamide
• Dioxane refers to 1, 4-dioxane.
• DMAP refers to 4dimethylaminopyridine.
• DIPEA diisopropylethylamine
• TMSCl refers to trimethylchlorosilane.
• LDA lithium diisopropylamide
• Selectflour refers to selective fluoride reagent.
• EDC ⁇ HCl refers to 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride.
• TBTU refers to O-benzotriazol-N,N,N',N'-tetramethyluronium tetrafluoroborate.
• NBS N-bromosuccinimide
• Optional or “optionally” means that the subsequently described event or the circumstance can, but need not occur. Its meaning includes the instances in which the event or the circumstance does or does not occur.
• heterocyclyl optionally substituted by alkyl means that the alkyl group can be, but need not be present. Its meaning includes the instances in which heterocyclyl is unsubstituted or substituted with alkyl.
• Substituted means that one or more hydrogen atoms in a group are each independently substituted by the corresponding number of the substituents. Consequently, the substituents are only positioned at their possible chemical positions, and the possible or impossible substitutions can be determined (through experiments or theory) by those skilled in the art without paying excessive efforts. For example, the combination of amino or hydroxy having free hydrogen and carbon atoms having unsaturated bonds (such as olefinic) may be unstable.
• “Pharmaceutical composition” refers to a mixture comprising one or more of the compounds described herein or the physiological/pharmaceutical salts or prodrugs thereof and other chemical components, such as physiological/pharmaceutical carriers and excipients.
• the purpose of the pharmaceutical composition is to facilitate administration of a compound to an organism, which will help absorption of the active ingredient, thereby realizing biological activity.
• NMR nuclear magnetic resonance
• LC-MS liquid chromatography-mass spectrometry
• LC-MS Liquid chromatography-mass spectrometry
• HPLC is determined on an Agilent 1200 Infinity Series mass spectrometer.
• HPLC is determined on an Agilent 1200DAD high pressure liquid chromatographic instrument (Sunfire C18 150 ⁇ 4.6 mm chromatographic column) and a Waters 2695-2996 high pressure liquid chromatographic instrument (Gimini C18 150 ⁇ 4.6 mm chromatographic column).
• TLC thin-layer silica gel chromatography
• Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate is used for thin-layer silica gel chromatography (TLC).
• the dimension of the plates used in TLC is 0.15 mm to 0.2 mm, and the dimension of the plates used in product purification is 0.4 mm to 0.5 mm.
• Column chromatography generally uses Yantai Huanghai 200 to 300 mesh silica gel as carrier.
• the starting materials used in the examples of the present invention are known and commercially available, or can be synthesized by adopting or according to the known method in the art.
• Methyl 6 ⁇ -ethyl-chenodeoxycholicate 10-i (96 mg, 0.22 mmol) was dissolved in 2.5 mL of ethanol, and added with hydrazine hydrate (0.5 mL, 85%). The mixture was heated to reflux for 7 hours until completed basically. After cooling to the room temperature, the mixture was washed with saturated brine and extracted with ethyl acetate three times. The organic phases were combined and dried over anhydrous sodium sulfate, and then filtered. The filtrate was concentrated under reduced pressure to obtain compound 10-ii(87 mg, 91%).
• 6 ⁇ -Ethyl-chenodeoxycholic acid ( OCA , 42 mg, 0.10 mmol) was dissolved in 1 mL of dry N, N-dimethylformamide, and added with triethylamine (28 ⁇ L, 0.20 mmol) and ethyl chloroformate (11 ⁇ L, 0.11 mmol) successively in a ice water bath. The mixture was stirred for 30 minutes, and then added with 2.0 M solution of ammonia in methanol (0.10 mL, 0.20 mmol). The reaction mixture was warmed to room temperature and stirred for 2 hours untile completed. The reaction solution was concentrated under reduced pressure to give a crude product which was used directly in the next step.
• N,N-dimethylformamide dimethyl acetal (2 mL) was added to the above crude product, and the mixture was heated to reflux for 2 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was dissolved in 2 mL of acetic acid and then added with hydrazine hydrochloride (21 mg, 0.20 mmol). The reaction solution was heated to 90°C and stirred for 90 minutes. The reaction solution was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phase was washed with saturated aqueous NaHCO 3 , dried over anhydrous sodium sulfate, and filtered.
• 6 ⁇ -Ethyl-chenodeoxycholic amide 12-i (210 mg, 0.50 mmol) was dissolved in 5 ml of tetrahydrofuran, and then added with triethylamine(0.56 mL, 4.0 mmol) and trifluoroacetic anhydride (0.28 mL, 2.0 mmol) successively in an ice-water bath. The mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction solution was quenched with saturated aqueous NaHCO 3 solution and extracted with ethyl acetate twice.
• Methyl 6 ⁇ -ethyl-chenodeoxycholicate 10-ii (43 mg, 0.10 mmol) was dissolved in 2 mL of chloroform, and then added with pyridine (12 ⁇ L, 0.15 mmol, 1.5 eq.) and oxalyl chloride monoethyl ester (13 ⁇ L, 0.12 mmol, 1.2 eq.) successively.
• the reaction mixture was heated to 80 °C and stirred for 2 hours until the reaction was completed basically.
• the reaction solution was concentrated under reduced pressure, and then washed with saturated brine and extracted with ethyl acetate three times. The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and filtrate was concentrated under reduced pressure.
• Methyl 6 ⁇ -ethyl-chenodeoxycholicate 1-ii (845 mg, 1.94 mmoL) was dissolved in 10 mL of dry tetrahydrofuran, and the mixture was cooled to -72 °C in an ice-ethanol bath.
• LDA solution (4.9 mL, 9.72 mmol, 2 M) was added dropwise over 15 minutes and further stirred for 15 min before addition of trimethylchlorosilane (1.0 mL, 11.7 mmol) dropwise.
• the reaction mixture was stirred for 4 hours at low temperature.
• N-bromosuccinimide (692 mg, 3.89 mmol) was dissolved in 5 ml of tetrahydrofuran and then added dropwise to the reaction system.
• reaction mixture was warmed to room temperature and stirred overnight. After TLC showed completion of the reaction, the reaction solution was quenched with 10 ml of water, and extracted with ethyl acetate three times. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain crude product 14-ii which was used directly in the next step.
• Methyl chenodeoxycholicate 15-i (348 mg, 0.86 mmoL) was dissolved in 5 mL of dry tetrahydrofuran and the mixture was cooled to -72 °C in an ice-ethanol bath.
• LDA solution (2.1 mL, 4.28 mmol, 2M) was added dropwise in 15 minutes and further stirred for 15min before addition of trimethylchlorosilane (0.44 mL, 5.14 mmol) dropwise .
• the reaction mixture was stirred for 4 hours at low temperature.
• N-bromosuccinimide (305 mg, 1.71 mmol) was dissolved in 5 ml of tetrahydrofuran and then added dropwise to the reaction system above.
• reaction solution was quenched with 10 ml of water, and extracted with ethyl acetate three times. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain crude product 15-ii which was used directly in the next step.
• FXR receptor binding activity assay time-resolved fluorescence detection method TR-FRET method
• the biochemical activity of the present compounds was determined by the above test, and the EC 50 values measured were shown in the table below.
• Transfection reagent was Fugene HD (Promega#E231A) (1) Preparing the transfection mixture according to the following table pBIND-FXR(ng/well) 25 pG5Luc(ng/well) 25 FuGENE HD( ⁇ l/well) 0.15 Serum-free medium ( ⁇ l/well) 1.85 Total mixture ( ⁇ l/well) 2.5 (2) The mixture in the tube was vigorously mixed and incubated at room temperature for 15 minutes; (3) Digesting the cells in the culture dish and counting; (4) Diluting the cell suspension to the desired volume of 600,000/ml (96-well plates 100 ⁇ l /well); (5) Adding the required volume of the transfection mixture to the cell suspension, followed plating at 100 ⁇ l/well; (6) Incubateing for 24 hours under 37 °C 5% CO 2 humid conditions. 3. Treatment of the compound
• the pharmacokinetic study of the present invention was performed in rats.
• the pharmacokinetic behavior of the positive control INT-747 and the representative compound of the present invention such as Example 14- ⁇ in rats was studied, and their pharmacokinetic characteristics were evaluated.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Immunology (AREA)
• Child & Adolescent Psychology (AREA)
• Endocrinology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Emergency Medicine (AREA)
• Steroid Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57198149

Family Applications (1)

Country Status (6)

Cited By (13)

Families Citing this family (19)

Family Cites Families (13)

• 2016
  • 2016-04-13 CN CN201680012567.8A patent/CN107250150B/zh active Active
  • 2016-04-13 CN CN201910026222.3A patent/CN111116699B/zh active Active
  • 2016-04-13 US US15/569,918 patent/US20180148470A1/en not_active Abandoned
  • 2016-04-13 WO PCT/CN2016/079167 patent/WO2016173397A1/fr active Application Filing
  • 2016-04-13 EP EP16785828.1A patent/EP3290429A1/fr not_active Withdrawn
  • 2016-04-13 JP JP2017552445A patent/JP2018519246A/ja active Pending
  • 2016-04-21 TW TW105112405A patent/TW201638067A/zh unknown

Also Published As

Similar Documents

Legal Events